Skip Navigation

Center for Cancer Genome Discovery

  • The Center for Cancer Genome Discovery (CCGD) is the research and development group within the Precision Cancer Medicine effort at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Boston Children’s Hospital. We develop, evaluate, and implement novel technologies at the forefront of genome science in order to detect genetic alterations in tumors within the context of Precision Cancer Medicine.

    About Us

    The mission of the Center for Cancer Genome Discovery (CCGD) is to advance precision cancer medicine by developing new technologies for the analysis of cancer genomes and to provide basic, translational, and clinical investigators with access to these technologies.

    Matthew Meyerson, MD, PhD, and William Hahn, MD, Phd

    The three main components of our mission are:

    • Technology development: To develop new technologies for the analysis of cancer genomes
    • Collaborations: To provide access to these genomic technologies to basic, translational, and clinical investigators at Dana-Farber and beyond
    • Translation: To translate technologies to the clinical setting

    More specifically, we focus on the discovery of genomic alterations in human cancer and evaluate the clinical significance of these alterations for cancer diagnosis and therapy. Our next-generation sequencing platforms allow us to detect the full range of genomic alterations, including:

    • Single nucleotide variants
    • Insertions and deletions
    • Chromosomal rearrangements: translocations, inversions, duplications
    • Copy number changes
    • Expression changes
    • Allele-specific expression
    • Detection and quantification of gene fusion

    An integral aspect of the Center's mission is working toward more effective clinical trial designs, in which patients with similar genetically defined cancers will receive drugs designed to target specific genetic aberrations. In addition to the main areas indicated above, CCGD is available to assist collaborators with funding (e.g., grant submissions), experimental design, and coordination of each project through the appropriate channels.

    Our Structure

    Bioinformatics diagram

    CCGD is the research and development group within the Precision Cancer Medicine effort at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Boston Children's Hospital.

    Profile's mission is to implement these technologies in a CLIA-certified clinical environment with two major aims: potentially identify genetic variants that can dictate targeted therapies that are most likely to be effective in individual patients; and populate a comprehensive research database linking patient clinical data with genetic findings across a wide array of tumor types.

    The Bioinformatics group bridges both efforts by developing sophisticated analytical tools that mine the sequence data, translating results into research and clinical information.

    Learn more about this initiative

  • Newest Technologies

    Integrative RNA Sequencing

    RNAseq (targeted or whole transcriptome) can add functionality to DNAseq by quantifying expression of the mutant allele or downstream genes in the pathway.

    HiSeq 3000

    New patterned flow cell provides even spacing of sequencing clusters to deliver significant increases in sequencing reads and total output of the system.

    RobustCNV

    Copy number variants are now being identified using RobustCNV, a new algorithm developed at the Center for Cancer Genome Discovery (CCGD).

    Customize Your Sequencing

    Design, mix, and match any genomic region in a custom baitset – targeted panels, exome+, translocations, promoters, enhancers. CCGD will take care of it.